NovoSeven® is indicated for the treatment of bleeding episodes and for the prevention of bleeding in surgery or invasive procedures in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX, congenital haemophilia expected to have a high anamnestic response to factor VIII or factor IX, acquired haemophilia, congenital FVII deficiency, and Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions or where platelets are not readily available.1
NovoSeven® is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.1,3
1. NovoSeven® Summary of Product Characteristics. SFDA Label.
2. Maahs J et al. J Blood Med. 2014;5:153–156.
3. Committee for Medicinal Products for Human Use (CHMP), “CHMP extension of indication variation assessment report (NovoSeven®), `EPAR’”; 22 April 2022. Procedure No. EMEA/H/C/000074/II/0116.
4. Chowdary P et al. Res Pract Thromb Haemost 2019; 3:542-554.
5.Esperoct® Summary of Product Characteristics
6. NovoThirteen® Summary of Product Characteristics.